- $56.13bn
- $75.31bn
- $28.43bn
Annual cashflow statement for Medline, fiscal year end - December 31st, millions except per share.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | — | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | |
| Standards: | — | USG | USG | USG |
| Status: | fx Preliminary | Final | Final | Final |
| Net Income/Starting Line | — | 234 | 1,200 | 1,157 |
| Depreciation | ||||
| Deferred Taxes | ||||
| Non-Cash Items | — | 325 | 291 | 359 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | — | 199 | -675 | -783 |
| Change in Accounts Receivable | ||||
| Change in Inventories | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | — | 1,685 | 1,769 | 1,744 |
| Capital Expenditures | — | -275 | -354 | -447 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | — | -37 | -1,139 | -27 |
| Acquisition of Business | ||||
| Sale of Business | ||||
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Other Investing Cash Flow | ||||
| Cash from Investing Activities | — | -312 | -1,493 | -474 |
| Financing Cash Flow Items | — | -114 | -1,530 | -554 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | — | -191 | -1,613 | 399 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | — | 1,186 | -1,335 | 1,692 |